Clinical trials: Glaucoma Open-angle
- Condition Glaucoma Open-angle
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Primary Open Angle Glaucoma
The Effects of Visior on Ocular Hemodynamics
To determine the relationship between the affects of viewing commercially available content through the VISIOR video goggles and ocular blood flow in glaucoma patients and healthy subjects.
- Trial name
- NCT02959593
- Testing
- VISIOR video goggles
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Visior Technologies Ltd.
Primary Open Angle Glaucoma (POAG)
One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects
The purpose of this study is to evaluate the safety and efficacy of the intraocular pressure (IOP) lowering effect of one, two, or three iStent devices in eyes of subjects previously on two anti-glaucoma medications.
- Trial name
- NCT01517477
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma
Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution
This is a double-masked, placebo-controlled study which will determine the action of NCX 470 ophthalmic solution, 0.1% on aqueous humor dynamic parameters in healthy volunteers or subjects with OHT.
- Trial name
- Whistler (NCT05938699)
- Testing
- NCX 470
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Nicox Ophthalmics, Inc.
Glaucoma, Ocular Hypertension
This Follow-up Extension Study is Aimed to Monitor the Long-term IOP-lowering Performance/Efficacy and Safety of the MINT® Procedure in Open Angle Glaucoma Eyes.
This follow-up extension study is planned to invite all patients who underwent the MINT® surgery and completed Month 24 Visit in the prior MMS EEU-7 study.
- Conditions
- Glaucoma, Ocular Hypertension, Open-Angle Glaucoma
- Trial name
- NCT07081347
- Testing
- MINT Minimally Invasive Nasal Trabeculostomy
- Where
- Armenia
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Sanoculis Ltd
Healthy Volunteers
Bimatoprost Ocular Insert Pharmacokinetic Study
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02444767
- Testing
- 13mg Bimatoprost Ocular Insert
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- ForSight Vision5, Inc.
Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder)
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
The goal of this clinical trial is to learn if a new contact lens device can record patterns in eye pressure for 24 hours in adults with glaucoma and in healthy participants.
- Conditions
- Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH)
- Trial name
- NCT06689696
- Testing
- miLens system
- Where
- 3 sites in United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Smartlens, Inc.
Primary Open-angle Glaucoma
GORE Glaucoma Drainage Implant Clinical Study Dominican Republic
The objective of this early feasibility clinical study is to evaluate the safety and effectiveness of several different GORE Glaucoma Drainage Implant configurations in subjects with primary open-angle glaucoma that is…
- Trial name
- NCT05557058
- Testing
- Gore Glaucoma Device Implant (GORE GDI)
- Where
- Dominican Republic
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- W.L.Gore & Associates
Subjects With Primary Open-angle Glaucoma (POAG)
Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of two iStent devices in eyes of subjects with primary open-angle glaucoma
- Trial name
- NCT01252862
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Subjects With Primary Open-angle Glaucoma (POAG)
Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents
The purpose of this study is to assess efficacy and safety of two iStents for the reduction of intraocular pressure associated with primary open-angle glaucoma.
- Trial name
- NCT01252888
- Testing
- iStents
- Where
- Armenia
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Primary Open Angle Glaucoma (POAG)
iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.
- Trial name
- NCT03478293
- Testing
- iStent inject surgery
- Where
- Brazil
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma
Combined Phacoemulsification With iStent Inject W Versus Hydrus for Mild to Moderate Open Angle Glaucoma
The goal of the study is to prospectively evaluate and compare Hydrus microstent to the iStent Inject Wide in combination with cataract surgery in patients with mild to moderate open angle glaucoma.
- Trial name
- NCT05583591
- Testing
- Combined cataract surgery with Hydrus microstent, Combined cataract surgery with iStent Inject W
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Diablo Eye Associates
Ocular Hypertension, Open-Angle Glaucoma
A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma
The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).
- Trial name
- NCT02743780
- Testing
- MGV354 ophthalmic suspension
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma, Healthy Subjects
Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor
The objectives of this study are to assess the safety and effectiveness of the SENSIMED Triggerfish® (TF) device in continuous recording of relative fluctuation in intraocular pressure (IOP).
- Trial name
- NCT01390779
- Testing
- SENSIMED Triggerfish
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sensimed AG
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution
The purpose of this Phase 1b study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AKB-9778 ophthalmic solution (eye drops) administered for 7 days in adults.
- Trial name
- NCT04284514
- Testing
- AKB-9778 Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Aerpio Therapeutics
Primary Open Angle Glaucoma (POAG)
Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects
The purpose of this study is to evaluate the safety and efficacy of the iStent medical device that is implanted into the eye and designed to reduce eye pressure in patients with your condition.
- Trial name
- NCT01252849
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle, Healthy
Sensing Contact Lens-based Device for 24-hour Monitoring of Intraocular Pressure
Glaucoma is characterized by irreversible vision loss through the progressive death of optic nerve fibers unless timely diagnosis and adequate treatment are provided.
- Trial name
- NCT03689088
- Testing
- Goldfish, Tonometry
- Where
- Poland
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Sensimed AG
OAG - Open-Angle Glaucoma
Evaluation of the Compatibility of Different Eye Lid Retractors to the Direct Selective Laser Trabeculoplasty (DSLT) Procedure
Direct Selective Laser Trabeculoplasty (DSLT) is an emerging therapeutic technology to treat glaucoma. DSLT was previously tested in 2 clinical trials and demonstrated promising safety and efficacy results in reducing the…
- Trial name
- NCT05271734
- Testing
- Lid retractor placement
- Where
- Georgia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BelkinVision
Glaucoma, Open Angle Glaucoma
Performance and Safety of the ARGOS-SC Suprachoroidal Pressure Sensor in Patients With Glaucoma Undergoing Non-penetrating Glaucoma Surgery
The purpose of this study is to evaluate both the safety and feasibility of the surgical implantation of the ARGOS-SC implant during non-penetrating glaucoma surgery and the safety and usability of the ARGOS-SC implant and system…
- Trial name
- ARGOS-SC01 (NCT03756662)
- Testing
- ARGOS-SC suprachoroidal pressure sensor
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Implandata Ophthalmic Products GmbH
Subject With Primary Open-angle Glaucoma (POAG)
A Prospective Evaluation of Open-Angle Glaucoma Subjects on Two Topical Hypotensive Medications Treated With One Suprachoroidal Stent
The purpose of this study is to assess the efficacy and safety of one iStent supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma.
- Trial name
- NCT01252914
- Testing
- iStent Supra Stent
- Where
- Armenia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Glaucoma Open-Angle Primary, Ocular Hypertension
Open-Label Study of Safety of H1337 in Healthy Volunteers
The trial will evaluate the safety of one dose regimen of H-1337 [1% twice daily (b.i.d.)] in both eyes in healthy volunteers.
- Trial name
- NCT06572397
- Testing
- H-1337 1.0%
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- D. Western Therapeutics Institute, Inc.